ClinicalTrials.gg
DrugBiological

Teplizumab clinical trials

Also written MGA031, TZIELD and SAR446681.

studies test it
13
open now
2
in phase 3
4
first study started
2002

How each study uses teplizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the teplizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
17 Nov 2022 · TZIELD · BLA 761183 (FDA, Drugs@FDA)
European Union
8 Jan 2026 · Teizeild · EMEA/H/C/005496 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Teplizumab
10
hOKT3gamma1(Ala-Ala)
2

Brand

TZIELD
2

Development codes

MGA031
3
SAR446681
2

Studies by the year they started

12 studies that test it; most in 2006 (2); 1 more planned to start later

Studies that test teplizumab, by start year
YearStudies
20021
20062
20092
20101
20181
20191
20201
20231
20252

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
8
Phase 3
4
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 9 · Other 4

Sanofi (3) · MacroGenics (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Provention Bio, a Sanofi Company (1) · Provention Bio, Inc. (1) · Precigen Actobio T1D, LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Abdullah Kars (1)

Often tested with

Tested in the same studies.

AG019 (1)

Related medicines

As reviewed, each with the page that says it.

Studies

Open first, then newest update. How each study uses teplizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 13

As the comparator · 1 — what is tested is compared with teplizumab

Codes

What other systems call teplizumab · ClinicalTrials.gg INT004800

  • MeSH (NLM) C502540teplizumabConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) S4M959U2IJTEPLIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 2621880One source FDA
  • Wikidata Q7701358teplizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C88647TeplizumabOne source FDA
  • DrugBank DB06606One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.